Common Contracts
34 similar Underwriting Agreement contracts by Adma Biologics, Inc., Alerus Financial Corp, Byrna Technologies Inc., others
UNDERWRITING AGREEMENTUnderwriting Agreement • December 7th, 2022 • Adma Biologics, Inc. • Biological products, (no disgnostic substances) • New York
ADMA Biologics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 20,979,020 shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of 20,979,020 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 3,146,853 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
2,500,000 Shares* BYRNA TECHNOLOGIES INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 22nd, 2021 • Byrna Technologies Inc. • Miscellaneous electrical machinery, equipment & supplies • New York
Byrna Technologies Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of 2,500,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), to the several Underwriters named in Schedule I (the “Underwriters”) to this agreement (the “Agreement”), for whom Raymond James & Associates, Inc. (“Raymond James”) is acting as the representative (the “Representative”). In addition, the Company has agreed to sell to the Underwriters an option (the “Option”) to purchase up to an additional 375,000 shares of Common Stock (the “Additional Shares”) on the terms and condition stated herein. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.”
2,250,000 Shares* BYRNA TECHNOLOGIES INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 12th, 2021 • Byrna Technologies Inc. • Miscellaneous electrical machinery, equipment & supplies • New York
Byrna Technologies Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of 2,250,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), to the several Underwriters named in Schedule I (the “Underwriters”) to this agreement (the “Agreement”), for whom Raymond James & Associates, Inc. (“Raymond James”) is acting as the representative (the “Representative”). In addition, the Company has agreed to sell to the Underwriters an option (the “Option”) to purchase up to an additional 337,500 shares of Common Stock (the “Additional Shares”) on the terms and condition stated herein. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.”
7,875,000 Shares1 PLx Pharma Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 3rd, 2021 • PLx Pharma Inc. • Pharmaceutical preparations • New York
PLx Pharma Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 7,875,000 shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of 7,875,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 1,181,250 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
14,285,714 Shares1 LIPOCINE INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 27th, 2021 • Lipocine Inc. • Pharmaceutical preparations • New York
Lipocine Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 14,285,714 shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of 14,285,714 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 2,142,857 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
EX-1.1 2 a18-8840_1ex1d1.htm EX-1.1 1,866,667 Shares(1)* LEAP THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT St. Petersburg, Florida March 23, 2018 RAYMOND JAMES & ASSOCIATES, INC. LADENBURG THALMANN & CO. INC. As Representatives of the...Underwriting Agreement • May 5th, 2020 • New York
Leap Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 1,866,667 shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of 1,866,667 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 280,000 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. and Ladenburg Thalmann & Co. Inc. are acting as the representatives of the several Underwriters and in such capacity is referred to in this Agreement as the “Representatives.”
Shares* AVADIM HEALTH, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 17th, 2020 • Avadim Health, Inc. • Perfumes, cosmetics & other toilet preparations • New York
Avadim Health, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. and SunTrust Robinson Humphrey, Inc. are acting as the representatives of the several Underwriters and in such capacity are referred to in this agreement (the “Agreement”) as the “Representatives.”
] Shares(1) ALERUS FINANCIAL CORPORATION Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 16th, 2019 • Alerus Financial Corp • National commercial banks • New York
Alerus Financial Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of [ ] shares of the Company’s Common Stock, par value $1.00 per share (the “Common Stock”). The aggregate of [ ] shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional [ ] shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this agreement (this “Agreement”) as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as “you” or the “Representative.”
] Shares(1) ALERUS FINANCIAL CORPORATION Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 2nd, 2019 • Alerus Financial Corp • National commercial banks • New York
Alerus Financial Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of [ ] shares of the Company’s Common Stock, par value $1.00 per share (the “Common Stock”). The aggregate of [ ] shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional [ ] shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this agreement (this “Agreement”) as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as “you” or the “Representative.”
8,368,200 Shares* ADMA Biologics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 8th, 2018 • Adma Biologics, Inc. • Biological products, (no disgnostic substances) • New York
ADMA Biologics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 8,368,200 shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of 8,368,200 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 1,255,230 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
LEAP THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 23rd, 2018 • Leap Therapeutics, Inc. • Pharmaceutical preparations • New York
Leap Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 1,866,667 shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of 1,866,667 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 280,000 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. and Ladenburg Thalmann & Co. Inc. are acting as the representatives of the several Underwriters and in such capacity is referred to in this Agreement as the “Representatives.”
16,976,744 Shares* ADMA Biologics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 9th, 2017 • Adma Biologics, Inc. • Biological products, (no disgnostic substances) • New York
ADMA Biologics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 16,976,744 shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of 16,976,744 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 2,546,511 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
●] Shares* ADMA Biologics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 3rd, 2017 • Adma Biologics, Inc. • Biological products, (no disgnostic substances) • New York
ADMA Biologics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of [●] shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of [●] shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional [●] shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
510,638 Shares FS BANCORP, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 11th, 2017 • FS Bancorp, Inc. • Savings institutions, not federally chartered • New York
FS Bancorp, Inc., a Washington corporation (the "Company"), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the "Underwriters"), an aggregate of 510,638 shares of its Common Stock, $0.01 par value per share (the "Common Stock"). The aggregate of 510,638 shares to be purchased from the Company are called the "Firm Shares." In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 76,596 shares of Common Stock (the "Additional Shares") to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this agreement (this "Agreement") as the "Shares." Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as "you" or the "Representative."
Shares* Avenue Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 22nd, 2017 • Avenue Therapeutics, Inc. • Pharmaceutical preparations • New York
Avenue Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of [__________] shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of [_______] shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional [________] shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
2,380,953 Shares* Bank of Commerce Holdings Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 10th, 2017 • Bank of Commerce Holdings • State commercial banks • California
Bank of Commerce Holdings, a California corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 2,380,953 shares of its Common Stock, no par value per share (the “Common Stock”). The aggregate of 2,380,953 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 357,143 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
2,400,000 Shares* HOWARD BANCORP, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 1st, 2017 • Howard Bancorp Inc • State commercial banks • Florida
Howard Bancorp, Inc., a Maryland corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 2,400,000 shares of its Common Stock, par value $0.01 per share (the “Common Stock”). The aggregate of 2,400,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 360,000 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
1,571,429 Shares* CAROLINA FINANCIAL CORPORATION Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 25th, 2017 • Carolina Financial Corp • State commercial banks • Florida
Carolina Financial Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 1,571,429 shares of its Common Stock, par value $0.01 per share (the “Common Stock”). The aggregate of 1,571,429 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 235,714 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
Shares PARAGON COMMERCIAL CORPORATION Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 10th, 2016 • Paragon Commercial CORP • State commercial banks • Florida
1,892,308 Shares* ADMA Biologics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 28th, 2016 • Adma Biologics, Inc. • Biological products, (no disgnostic substances) • New York
ADMA Biologics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 1,892,308 shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of 1,892,308 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 283,846 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
3,769,231 Shares* VOLITIONRX LIMITED Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 18th, 2016 • Volitionrx LTD • In vitro & in vivo diagnostic substances • New York
VolitionRx Limited, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 3,769,231 shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of 3,769,231 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 565,384 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
Shares* PLx Pharma Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 15th, 2016 • PLX Pharma Inc. • Pharmaceutical preparations • New York
PLx Pharma Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of [__________] shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of [_______] shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional [________] shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. (“RJ&A”) is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
Shares* PLx Pharma Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 5th, 2016 • PLX Pharma Inc. • Pharmaceutical preparations • New York
PLx Pharma Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of [__________] shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of [_______] shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional [________] shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. (“RJ&A”) is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
1,967,214 Shares* CAROLINA FINANCIAL CORPORATION Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 14th, 2015 • Carolina Financial Corp • State commercial banks • Florida
Carolina Financial Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 1,967,214 shares of its Common Stock, par value $0.01 per share (the “Common Stock”). The aggregate of 1,967,214 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 295,082 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
600,000 Shares FIRST GUARANTY BANCSHARES, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 12th, 2015 • First Guaranty Bancshares, Inc. • Savings institution, federally chartered • New York
ADMA Biologics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 13th, 2015 • Adma Biologics, Inc. • Biological products, (no disgnostic substances) • New York
ADMA Biologics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 1,225,000 shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of 1,225,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 183,750 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
2,640,000 Shares COVENANT TRANSPORTATION GROUP, INC. Class A Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 25th, 2014 • Covenant Transportation Group Inc • Trucking (no local) • New York
Covenant Transportation Group, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 2,640,000 shares (the “Firm Shares”) of the Company’s Class A Common Stock, par value $0.01 per share (the “Common Stock”). In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 396,000 shares of Common Stock. The additional 396,000 shares to be sold by the Company are referred to in this Underwriting Agreement (this “Agreement”) as the “Additional Shares.” The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Stephens Inc. and BB&T Capital Markets, a division of BB&T Securities, LLC, are acting as the representatives of the several Underwriters and in such capacity are referred to in this Agreement as the “Representat
2,051,283 Shares* FEDERATED NATIONAL HOLDING COMPANY Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 1st, 2014 • Federated National Holding Co • Fire, marine & casualty insurance • Florida
Federated National Holding Company, a Florida corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 2,051,283 shares of its Common Stock, par value $0.01 per share (the “Common Stock”). The aggregate of 2,051,283 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 307,692 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
2,418,605 Shares* FEDERATED NATIONAL HOLDING COMPANY Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 20th, 2013 • Federated National Holding Co • Fire, marine & casualty insurance • Florida
Federated National Holding Company, a Florida corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 2,418,605 shares of its Common Stock, par value $0.01 per share (the “Common Stock”). The aggregate of 2,418,605 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 362,790 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
18,000,000 Shares First Busey Corporation Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 29th, 2009 • First Busey Corp /Nv/ • State commercial banks • New York
4,000,000 Shares Cardinal Financial Corporation Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 22nd, 2009 • Cardinal Financial Corp • National commercial banks • New York
Cardinal Financial Corporation, a Virginia corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 4,000,000 shares of its Common Stock, par value $1.00 per share (the “Common Stock”). The aggregate of 4,000,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 600,000 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are collectively referred to in this underwriting agreement (the “Agreement”) as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
3,000,000 Shares* Amedisys, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 3rd, 2006 • Amedisys Inc • Services-home health care services • New York
Amedisys, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 3,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The aggregate of 3,000,000 shares of Common Stock to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 450,000 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
1,500,000 Shares* MAIN STREET BANKS, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 9th, 2004 • Main Street Banks Inc /New/ • Commercial banks, nec • Florida
Main Street Banks, Inc., a Georgia corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 1,500,000 shares of its Common Stock, no par value per share (the “Common Stock”). The aggregate of 1,500,000 shares of Common Stock to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 225,000 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. (“Raymond James”) and SunTrust Capital Markets, Inc. are acting as the representatives of the several Underwriters and in such capacity are referred to in this Agreement as the “Representa
4,800,000 SHARES ARGONAUT GROUP, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 31st, 2003 • Argonaut Group Inc • Fire, marine & casualty insurance • Texas
Argonaut Group, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 4,800,000 shares of its common stock, par value $0.10 per share (the “Common Stock”). The aggregate of 4,800,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 720,000 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
